MSB (ASX) Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

Originally posted by yelrom: ↑

Being in London, I got into the habit of waiting up for any announcement before hitting the sack. Last night I fell asleep watching Chelsea and woke up with the announcement made and the markets opened. Tonight I fell asleep watching Tottenham but fortunately woke up in time to see them knocked out of the Champions League. It really is a good time (after too many years) to be an Arsenal supporter.
The acceptance is as has been articulated by many a post wonderful news. The culmination of a measured approach of positive engagement with the FDA since the CRL. Although the full story of this has yet to be told, I cannot help but to believe that Krause has been a big part of that positive engagement.
We are “relatively” on the last lap before approval, the first of many for this cutting edge treatment. The off label use will perhaps be the best showcase for its potential. If you were an adult with Grade 3 or 4 SRGvHD, what would you want Rux or REM? Absolute no brainier “Mr RCT!
The attack by shorters aided I expect by large holders who lend the shares show why this practice should be outlawed. They are in effect extorting from the small retail shareholder and another example of crony capitalism which blights the western world.
So at the end of the day’s trading the good news was attacked by short sellers and “bad actors” on forums such as this. The share price did rise but no where near what it should. Closed higher on Nasdaq despite more attacks but what was a clear blue water price rise than on the ASX. Yet again this morning it appears they are trying to push it down when it should be leap frogging.
The solution?
Another “Reddit Revolution” would be perfect as the small investor “bites back”, but in this case (imo) buying into a company with real prospects of massive growth and profits. But realistically unless some amazing partnership/revenue share of some sort is announced in the next few months we are going to require a capital raise. Always in some ways a little unpalatable but our upside is such that we will still do well with those buying at these levels even more so as (imo) incredibly under valued with August just a few months away.
However we also need Itescu & Krause ably abetted by our wonderful medical supporters out and about banging the drum to the institutions. Some may have heard it before, but perhaps not this improved updated version validated by Krause and his knowledge of this critical approval stage.
We must move forward with the back trial so ideally it is up and running before the SRGvHD approval to turbo charge the excitement. New or returning institutional investors buying now would (and as someone suggested already on HC) if others who are lending are also buying, then the shorts will have to “run” as they will not be able to control the price as it is not an attack based on a suspected CRL share price collapse like last time we were up for approval.
Good to see the share price is fighting back this morning but it maybe difficult to maintain a real rally at this time, we shall see.

Regards
Yelrom

Expand

Msb is perfect for another retail run.. not enough shorts for a gamestop.. but deffo the blue sky idea. It only needs eyes. Never gotten them since that first 10 dollar run. Would be amazing to see a pump.

No.	Vol.	Price($)
2	14500	$1.10

No.

Vol.

Price($)

14500

$1.10

Price($)	Vol.	No.
$1.11	141676	5

Price($)

Vol.

No.

$1.11

141676

No.	Vol.	Price($)
2	14500	1.100
2	93112	1.095
2	37684	1.090
3	40400	1.085
2	61100	1.080

No.

Vol.

Price($)

14500

1.100

93112

1.095

37684

1.090

40400

1.085

61100

1.080

Price($)	Vol.	No.
1.110	141676	5
1.115	41050	3
1.120	157964	9
1.125	61233	3
1.130	111595	5

Price($)

Vol.

No.

1.110

141676

1.115

41050

1.120

157964

1.125

61233

1.130

111595

(20min delay)
Last $1.11		Change 0.010(0.91%)		Mkt cap ! $1.261B

Open	High	Low	Value	Volume
$1.09	$1.11	$1.07	$4.794M	4.399M

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-316

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-316

Top Stories

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News